Literature DB >> 2875725

Hepatobiliary disposition of vecuronium bromide in man.

A F Bencini, A H Scaf, Y J Sohn, U W Kersten-Kleef, S Agoston.   

Abstract

The plasma and bile concentrations, the biliary excretion and the neuromuscular blocking effect of vecuronium bromide were studied during surgery in 13 patients who had received 150 micrograms kg-1 i.v. The amount of vecuronium in liver biopsies taken after i.v injection was measured in a separate group of six patients. Vecuronium appeared early in the bile, in concentrations that were 30-50 times greater than those in the plasma. On the basis of the measured amount of vecuronium excreted in the bile, together with the accepted average daily bile flow, it was estimated that more than 40% of vecuronium was excreted in the bile in 24 h. Liver biopsies indicated that the liver may contain more than 50% of the i.v. dose 30 min after injection. The large distribution of vecuronium into the liver may account for the initial rapid decline in vecuronium plasma concentration and its relatively short duration of action. In this study, neuromuscular blockade was prolonged, possibly as a result of interference, by surgical manipulation, with the rapid hepatic uptake of vecuronium.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2875725     DOI: 10.1093/bja/58.9.988

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  11 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 2.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

Review 4.  Clinical pharmacokinetics of neuromuscular relaxants in pregnancy.

Authors:  J Guay; Y Grenier; F Varin
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 5.  Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations.

Authors:  D K Meijer; W E Mol; M Müller; G Kurz
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

6.  Oral clonidine does not alter vecuronium neuromuscular blockade in anaesthetized patients.

Authors:  H Takahashi; T Nishikawa
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

7.  Vecuronium neuromuscular block in patients with malignant obstructive jaundice.

Authors:  A Baraka
Journal:  Can J Anaesth       Date:  1994-08       Impact factor: 5.063

Review 8.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 9.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Pharmacokinetics and pharmacodynamics of vecuronium bromide.

Authors:  T Nomura
Journal:  J Anesth       Date:  1992-01       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.